Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Background Higher levels of inflammatory biomarkers are associated with an increased risk of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery (MINS). Colchicine is an anti-inflammatory drug that might reduce the incidence of these complications.Methods COP-AF was a randomised trial conducted at 45 sites in 11 countries. Patients aged 55 years or older and undergoing major non-cardiac thoracic surgery were randomly assigned (1:1) to receive oral colchicine 0 center dot 5 mg twice daily or matching placebo, starting within 4 h before surgery and continuing for 10 days. Randomisation was done with use of a computerised, web-based system, and was stratified by centre. Health-care providers, patients, data collectors, and adjudicators were masked to treatment assignment. The coprimary outcomes were clinically important perioperative atrial fibrillation and MINS during 14 days of follow-up. The main safety outcomes were a composite of sepsis or infection, and non-infectious diarrhoea. The intention-to-treat principle was used for all analyses. This trial is registered with ClinicalTrials.gov, NCT03310125.Findings Between Feb 14, 2018, and June 27, 2023, we enrolled 3209 patients (mean age 68 years [SD 7], 1656 [51 center dot 6%] male). Clinically important atrial fibrillation occurred in 103 (6 center dot 4%) of 1608 patients assigned to colchicine, and 120 (7 center dot 5%) of 1601 patients assigned to placebo (hazard ratio [HR] 0 center dot 85, 95% CI 0 center dot 65 to 1 center dot 10; absolute risk reduction [ARR] 1 center dot 1%, 95% CI -0 center dot 7 to 2 center dot 8; p=0 center dot 22). MINS occurred in 295 (18 center dot 3%) patients assigned to colchicine and 325 (20 center dot 3%) patients assigned to placebo (HR 0 center dot 89, 0 center dot 76 to 1 center dot 05; ARR 2 center dot 0%, -0 center dot 8 to 4 center dot 7; p=0 center dot 16). The composite outcome of sepsis or infection occurred in 103 (6 center dot 4%) patients in the colchicine group and 83 (5 center dot 2%) patients in the placebo group (HR 1 center dot 24, 0 center dot 93-1 center dot 66). Non-infectious diarrhoea was more common in the colchicine group (134 [8 center dot 3%] events) than the placebo group (38 [2 center dot 4%]; HR 3 center dot 64, 2 center dot 54-5 center dot 22).Interpretation In patients undergoing major non-cardiac thoracic surgery, administration of colchicine did not significantly reduce the incidence of clinically important atrial fibrillation or MINS but increased the risk of mostly benign non-infectious diarrhoea.Funding Canadian Institutes of Health Research, Accelerating Clinical Trials Consortium, Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario, Population Health Research Institute, Hamilton Health Sciences, Division of Cardiology at McMaster University, Canada; Hanela Foundation, Switzerland; and General Research Fund, Research Grants Council, Hong Kong.Copyright (c) 2023 Elsevier Ltd. All rights reserved.
Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial
Conen, David;Ke Wang, Michael;Popova, Ekaterine;Chan, Matthew T V;Landoni, Giovanni;Cata, Juan P;Reimer, Cara;McLean, Sean R;Srinathan, Sadeesh K;Reyes, Juan Carlos Trujillo;Grande, Ascension Martín;Tallada, Anna Gonzalez;Sessler, Daniel I;Fleischmann, Edith;Kabon, Barbara;Voltolini, Luca;Cruz, Patrícia;Maziak, Donna E;Gutiérrez-Soriano, Laura;McIntyre, William F;Tandon, Vikas;Martínez-Téllez, Elisabeth;Guerra-Londono, Juan Jose;DuMerton, Deborah;Wong, Randolph H L;McGuire, Anna L;Kidane, Biniam;Roux, Diego Parise;Shargall, Yaron;Wells, Jennifer R;Ofori, Sandra N;Vincent, Jessica;Xu, Lizhen;Li, Zhuoru;Eikelboom, John W;Jolly, Sanjit S;Healey, Jeff S;Devereaux, P J;Conen, David;Devereaux, PJ;Vincent, Jessica;Wang, Michael Ke;Wells, Jennifer R.;Healey, Jeff S.;Landoni, Giovanni;McIntyre, William F.;Popova, Ekaterine;Sessler, Daniel I.;Srinathan, Sadeesh K.;Amir, Mohammed;Bangdiwala, Shrikant I.;Bossard, Matthias;Chan, Matthew TV;Eikelboom, John W.;Fleischmann, Edith;Jolly, Sanjit;Montes, Felix Ramón;Reimer, Cara;Schmartz, Denis;Wang, Chew Yin;Ofori, Sandra N.;Blum, Steffen;Alvarez-Garcia, Jesus;Lo Bianco, Giuliana;Traquair, Hugh;Guerrero-Pinedo, Fernando Andres;Oleynick, Christopher;Meyre, Pascal B.;Méndez-Zurita, Francisco;Chiarella-Redfern, Helene;Marcucci, Maura;Donati, Francesco;Gonzalez-Osuna, Aranzazu;Minervini, Fabrizio;Moreno Weidmann, Zoraida;Guerra-Ramos, Jose M.;Dion, Gabriel;Ramos-Pachón, Anna;Borges, Flavia K.;de Sa Boasquevisque, Danielle;Mosconi, Maria Giulia;Amarenco, Pierre;Mitchell, L. Brent;Wyse, George;Cheng, Davy;McAlister, Finlay A.;Wells, George A.;Baskaran, Geethan;Burns, Andrew T.;Gennaccaro, Julia;Howe, Rosemary;Mastrangelo, Louise;Pettit, Shirley;Popovic, Michelle;Shahbaz, Subana;Tosh, Makayla;Zucchetto, Simona J.;Heenan, Laura;Lee, Shun Fu;Li, Zhuoru;Xu, Lizhen;Kabon, Barbara;Hoetzenecker, Konrad;Schweiger, Thomas;Reiterer, Christian;Zotti, Oliver;Bsuchner, Paul;Hochreiter, Beatrix;Taschner, Alexander;Adamowitsch, Nikolas;Horvath, Katharina;Hantáková, Nicole;Bidgoli, Javad;Huybrechts, Isabelle;Cappeliez, Serge;Neary, John D.;Shargall, Yaron;Tandon, Vikas;Finley, Christian;Agzarian, John;Hanna, Waël;Abdulrahman, Muammar;Lawrence, Kelly;Gregus, Krysten;Quraishi, Faraaz;Wikkerink, Spencer;Wallace, Christine;Prine, Merissa;Gregus, Emily;Hare, Jacqueline;Lombardo, Kristen;Fezia, Behashta;Columbus, Teresa;Rushton, Jacob;DuMerton, Deborah;Reid, Ken;Parlow, Joel;Chung, Wiley;Karizhenskaia, Maria;Malik, Aftab;Tanzola, Rob;Giles, Andrew;McLean, Sean R.;McGuire, Anna;Lohser, Jens;Lim, Shirley;Grey, Rebecca;Yee, John;Grant, Kyle;Lee, Alex L.;Choi, James J.;Dewar, Leith R.;Durkin, Christopher;Schisler, Travis;Hecht, Patrick;Hughes, Bevan;Kidane, Biniam;Liu, Richard;Tan, Lawrence;Gowing, Stephen;Buduhan, Gordon;Enns, Stephanie;Poole, Emma;Graham, Kristin;Dubik, Niina;Chin, Alex;Maziak, Donna E.;Seely, Andrew JE;Gilbert, Sebastien;Villeneuve, P. James;Sundaresan, Sudhir;Gingrich, Molly;Fazekas, Anna;Bucciero, Kirby;Malthaner, Richard A.;Lewis, Deb;Fortin, Dalilah;Qiabi, Mehdi;Nayak, Rahul;Plourde, Madelaine Marie;Haider, Tehmina;Murphy, Rowan;Sellers, Daniel;Donahoe, Laura;Lefebvre, Marco;Lanthier, Luc;Ko, Michael Augustine;Parente, David;Cheung, Victoria;Schieman, Colin;Bessissow, Amal;Wong, Randolph HL;Joynt, Gavin M.;Lam, Carmen KM;Lau, Rainbow WH;Wan, Innes YP;Underwood, Malcolm J.;Wu, William KK;Wong, Wai Tat;Choi, Gordon YS;Lee, Eva;Hui, Ka Yan;Fung, Beaker;Chan, Chee Sam;Ng, Fung Kei;Thung, Kin Hoi;Gutiérrez-Soriano, Laura;Castañeda, Laura Carmenza;Téllez, Luis Jaime;Ortiz-Ramirez, Lina Marcela;Baiardo-Redaelli, Martina;Belletti, Alessandro;Dieci, Elisa;Monaco, Fabrizio;Muriana, Piergiorgio;Nakhnoukh, Cristina;Novellis, Pierluigi;Turi, Stefano;Viscardi, Stefano;Veronesi, Giulia;Voltolini, Luca;Bongiolatti, Stefano;Salvicchi, Alberto;Gatteschi, Lavinia;Indino, Rossella;Tombelli, Simone;Ravasin, Alice;Salimbene, Ottavia;Rosboch, Giulio Luca;Balzani, Eleonora;Ceraolo, Edoardo;Neitzert, Luca;Brazzi, Luca;Londero, Francesco;Grossi, William;Massullo, Domenico;Fiorelli, Silvia;Margaritora, Stefano;Hashim, Shahrul Amry;Krishnasamy, Sivakumar;See, Woan Shiang;Nawaz, Mohammed Asghar;Bilal, Haris;Trujillo Reyes, Juan Carlos;Martínez-Téllez, Elisabeth;Belda Sanchis, Josep;Planas Canovas, Georgina;Libreros Niño, Alejandra;Parera Ruiz, Ana;Cladellas Gutierrez, Esther;Guarino, Mauro;Urrutia Cuchi, Gerard;Argilaga Nogues, Marta;Rovira Juan, Anna;Medina-Aedo, Melixa;Turró Castillejo, Mª Asunción;Gil Sanchez, Josep Mª;Araúz-Sarmiento, Ibell;Herranz Perez, Gracia;Chavarria Murillo, Stephania;Garcia-Osuna, Alvaro;Rodriguez-Arias, Ainhoa;Berga Garrote, Nuria;Martín Grande, Ascension;Parise Roux, Diego;Gajate Martín, Luis;De Pablo Pajares, Angélica;Candela Toha, Angel Manuel;Moreno Mata, Nicolás;Muñoz Molina, Gema;Caballero Silva, Usue;Cabañero, Alberto;Fra Fernandez, Sara;Cavestany García-Matres, Cristina;Simón, Luisa;Montenegro, Cristina;Pozo, Sergio;Gonzàlez-Tallada, Anna;González Suarez, Susana;Ribas Ball, Montserrat;De Nadal Clanchet, Miriam;Pérez Vélez, Javier;Cruz, Patrícia;Sánchez-Pedrosa, Guillermo;Duque, Patricia;González, Guillermo;Huerta, Luis;Rodríguez, Laura;Garutti, Ignacio;Ruiz-Villa, Laura;Martí-Ejarque, Maria del Mar;Gili-Bueno, Mireia;Maddio Vieyra, Ricardo Matias;Fibla, Juan J.;Durán, Núria;de Temple Pla, Marina;Rodríguez-Fuster, Alberto;Bermejo-Martínez, Silvia;Carramiñana, Albert;Opitz, Isabelle;Etienne, Harry;Cata, Juan P.;Guerra-Londono, Juan Jose;Rajaram, Ravi;Corrales, German;Vaporciyan, Ara;Mehran, Reza;Sepesi, Boris;Walsh, Garrett;Rice, David;Cukierman, Daniel S.;Swisher, Stephen;Marchant, Bryan E.;Harris, Lynne C.;Cusson, Bruce D.;Miller, Scott A.;Ayad, Sabry;Araujo, Jorge;Marquez-Roa, Leonardo;Hofstra, Richard L.;Wudel Jr.;Leonard J.;Minear, Steven C.;Teixeira, Camila;Pimentel, Mario;Popoff, Andrew M.;Marsack, Kelly;Meehan, Sarah;Chen, Tzonghuei H.;Essandoh, Michael;Poppers, Jeremy S.
2023-01-01
Abstract
Background Higher levels of inflammatory biomarkers are associated with an increased risk of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery (MINS). Colchicine is an anti-inflammatory drug that might reduce the incidence of these complications.Methods COP-AF was a randomised trial conducted at 45 sites in 11 countries. Patients aged 55 years or older and undergoing major non-cardiac thoracic surgery were randomly assigned (1:1) to receive oral colchicine 0 center dot 5 mg twice daily or matching placebo, starting within 4 h before surgery and continuing for 10 days. Randomisation was done with use of a computerised, web-based system, and was stratified by centre. Health-care providers, patients, data collectors, and adjudicators were masked to treatment assignment. The coprimary outcomes were clinically important perioperative atrial fibrillation and MINS during 14 days of follow-up. The main safety outcomes were a composite of sepsis or infection, and non-infectious diarrhoea. The intention-to-treat principle was used for all analyses. This trial is registered with ClinicalTrials.gov, NCT03310125.Findings Between Feb 14, 2018, and June 27, 2023, we enrolled 3209 patients (mean age 68 years [SD 7], 1656 [51 center dot 6%] male). Clinically important atrial fibrillation occurred in 103 (6 center dot 4%) of 1608 patients assigned to colchicine, and 120 (7 center dot 5%) of 1601 patients assigned to placebo (hazard ratio [HR] 0 center dot 85, 95% CI 0 center dot 65 to 1 center dot 10; absolute risk reduction [ARR] 1 center dot 1%, 95% CI -0 center dot 7 to 2 center dot 8; p=0 center dot 22). MINS occurred in 295 (18 center dot 3%) patients assigned to colchicine and 325 (20 center dot 3%) patients assigned to placebo (HR 0 center dot 89, 0 center dot 76 to 1 center dot 05; ARR 2 center dot 0%, -0 center dot 8 to 4 center dot 7; p=0 center dot 16). The composite outcome of sepsis or infection occurred in 103 (6 center dot 4%) patients in the colchicine group and 83 (5 center dot 2%) patients in the placebo group (HR 1 center dot 24, 0 center dot 93-1 center dot 66). Non-infectious diarrhoea was more common in the colchicine group (134 [8 center dot 3%] events) than the placebo group (38 [2 center dot 4%]; HR 3 center dot 64, 2 center dot 54-5 center dot 22).Interpretation In patients undergoing major non-cardiac thoracic surgery, administration of colchicine did not significantly reduce the incidence of clinically important atrial fibrillation or MINS but increased the risk of mostly benign non-infectious diarrhoea.Funding Canadian Institutes of Health Research, Accelerating Clinical Trials Consortium, Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario, Population Health Research Institute, Hamilton Health Sciences, Division of Cardiology at McMaster University, Canada; Hanela Foundation, Switzerland; and General Research Fund, Research Grants Council, Hong Kong.Copyright (c) 2023 Elsevier Ltd. All rights reserved.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/84593
Citazioni
ND
36
33
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
Errore
Errore
Informativa cookie
Utilizziamo cookie di prima e di terza parte per garantire la funzionalità del sito e per mostrare "le citazioni sociali (PLUMX)", "le pubblicazioni suggerite (core recommender)", "il grafico delle citazioni" e "le licenze dei fulltext". I Cookie di terze parti sono disattivati di default salvo esplicito consenso (Accetta tutti).
Preferenze cookie
Utilizzo dei cookie?
Utilizziamo i cookie per consentire il funzionamento del sito e per migliorare la tua esperienza online. Puoi scegliere per ogni categoria se abilitarli/disabilitarli quando vuoi. Per maggiori dettagli relativi ai cookie ed altri dati sensibili, puoi leggere la cookie policy e la privacy policy integrale.
Questi cookie sono essenziali per il funzionamento del nostro sito. Senza questi cookie, il sito potrebbe non funzionare correttamente.
Questi cookie consentono al sito di ricordare le scelte che hai eseguito in precedenza
Nome
Dominio
Durata
Descrizione
_pk.*
matomo.valueforyou.cineca.it
sessione
permette il tracciamento delle scelte fatte dall'utente
Questi cookie consentono al sito di accedere a funzionalità esterne
Nome
Dominio
Durata
Descrizione
s_.*
plu.mx
sessione
recupero grafico citazioni sociali da plumx
A_.*
core.ac.uk
7 giorni
recupero pubblicazioni consigliate per il pannello core-recommander
GS_.*
gstatic.com
richiesta http
visualizza grafico citazioni
CC_.*
creativecommons.org
richiesta http
visualizza licenza bitstream
Maggiori informazioni
Per qualsiasi domanda in relazione alle nostre policy sui cookie e sulle tue scelte, puoi visualizzare l'informativa completa a questo url.